Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial TNK and Albumin for Acute Stroke
NCT06113848Phase 3Unknown
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenecteplase and albumin (human) in ischemic stroke (4 arms), sponsored by Tianjin Huanhu Hospital. Primary endpoint: Number of participants with major response at 7 days. Status: unknown.
02
Drugs
tenecteplasealbumin (human)
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06113848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113848.